MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)
Study with an investigational drug in patients with recurrent or non-responsive colorectal cancer or other advanced solid tumors.
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
|Colorectal Cancer Advanced Solid Tumors||Drug: MK0457, VX-680 (Aurora Kinase Inhibitor)||Phase 1|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00099346
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|